Blinatumomab (MT103)

BIOLOGICAL2 trials

Sponsors

Amgen Research (Munich) GmbH

Conditions

Acute Lymphoblastic LeukemiaNon-Hodgkin's Lymphoma, Relapsed

Phase 1

Safety Study of the Bispecific T-cell Engager Blinatumomab (MT103) in Patients With Relapsed NHL

CompletedNCT00274742

Amgen Research (Munich) GmbHNon-Hodgkin's Lymphoma, Relapsed

Start: 2004-06-30End: 2012-04-30Updated: 2015-01-16

Phase 2

Phase II Study of the BiTE® Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)

CompletedNCT00560794

Amgen Research (Munich) GmbHAcute Lymphoblastic Leukemia

Start: 2008-01-31End: 2014-11-30Updated: 2015-01-26

Related Papers

Blinatumomab consolidation post–autologous stem cell transplantation in patients with diffuse large B-cell lymphoma

Blood Advances2023-10-238 citations

Relationship of T- and B-cell kinetics to clinical response in patients with relapsed/refractory non-Hodgkin lymphoma treated with blinatumomab

Experimental Hematology2021-07-036 citations

Long-term outcome of patients with relapsed/refractory B-cell non-Hodgkin lymphoma treated with blinatumomab

Blood Advances2019-08-2688 citations

LONG‐TERM OUTCOME OF PATIENTS WITH RELAPSED/REFRACTORY B‐CELL NON‐ HODGKIN LYMPHOMA TREATED WITH BISPECIFIC ANTIBODY BLINATUMOMAB IN A PHASE I TRIAL

Hematological Oncology2019-06-01

Pathogenesis-Based Development of Potential Mitigation Strategies for Blinatumomab-Associated Neurologic Events (NEs)

Blood2016-12-028 citations

A quantitative systems pharmacology (QSP) model to assess the action of blinatumomab in NHL patients (pts).

Journal of Clinical Oncology2016-05-204 citations

Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab.

2012-05-16361 citations